All Blogs

Aug 20, 2024

Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has recently achieved a significant milestone with the FDA's approval of AMONDYS 45 (casimersen). This antisense oligonucleotide, developed from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, is now approved for treati...

Jun 26, 2020

Cytomegalovirus (CMV) is a common herpes virus, and approximately 50 to 80 per cent of the adult US population has had a CMV infection by the time they turn 40. Once the virus infects an individual, it stays in their bodies in dormant form.  The estimates by DelveInsight suggest that the total number of dia...

Jun 25, 2020

Regeneron recognizes new combos to boost I-O drug Libtayo's cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance...

Jun 24, 2020

Alzheimer's is a progressive brain disorder that results in the degeneration of brain cells. It affects the thinking, reasoning, memory, and problem-solving skills of the person. Apart from cognitive function, it also influences mood, personality, behavior, and social skills. In the advanced stages, the patients ar...

Jun 23, 2020

Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases The engineered exosome technology is believed to improve the delivery of delivering gene therapy, gene editing and RNA technologies for ne...

Jun 22, 2020

The Geographic atrophy market size is anticipated to increase during the study period 2017–2030 owing to increasing GA prevalence, better understanding of disease pathophysiology, better therapies and pipeline candidates aimed at addressing the disease from its root. Geographic Atrophy (GA) is an advanced form ...

Jun 19, 2020

Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% by 2030 attributed to increasing DPN prevalence, and introduction to gene therapies in the pipeline. Diabetes prevalence has been on a gradual rise globally attributable to a paralleled rise in a sedentary lifestyle, obesity and inc...

Jun 18, 2020

Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and Longwood Fund and has an aim to create antibodies for cancer and fibrosis treatment. IL-11, a cytokine that plays a role in both disease are...

Jun 17, 2020

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...

Jun 16, 2020

The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized COVID-19 patients only when a clinical trial was unavailable, or participation in...